We and others have reported that the currently approved MKIs against HCC, SOR, as well as REG, transcriptionally inhibits ADAM9 [13, 15], whose concurrent enzymatic inhibition by leukotriene receptor antagonists is therefore presumed to further enhance the expression of mMICA. This evidence concerns the gene ADAM9 and hepatocellular carcinoma.